Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab (2018)
- Authors:
- USP affiliated authors: TIEZZI, DANIEL GUIMARÃES - FMRP ; ANDRADE, JURANDYR MOREIRA DE - FMRP
- Unidade: FMRP
- DOI: 10.1007/s40290-018-0247-5
- Subjects: NEOPLASIAS MAMÁRIAS; TERAPIA COMBINADA; QUIMIOTERAPIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Pharmaceutical Medicine
- ISSN: 1178-2595
- Volume/Número/Paginação/Ano: v. 32, n. 5, p. 319-325, 2018
- Status:
- Artigo aberto em periódico híbrido (Hybrid Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
PIMENTEL, Franklin Fernandes et al. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceutical Medicine, v. 32, n. 5, p. 319-325, 2018Tradução . . Disponível em: https://doi.org/10.1007/s40290-018-0247-5. Acesso em: 31 mar. 2026. -
APA
Pimentel, F. F., Morgan, G., Tiezzi, D. G., & Andrade, J. M. de. (2018). Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceutical Medicine, 32( 5), 319-325. doi:10.1007/s40290-018-0247-5 -
NLM
Pimentel FF, Morgan G, Tiezzi DG, Andrade JM de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab [Internet]. Pharmaceutical Medicine. 2018 ; 32( 5): 319-325.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1007/s40290-018-0247-5 -
Vancouver
Pimentel FF, Morgan G, Tiezzi DG, Andrade JM de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab [Internet]. Pharmaceutical Medicine. 2018 ; 32( 5): 319-325.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1007/s40290-018-0247-5 - Recurrence and survival after neoadjuvant chemotherapy for locally advanced cervical cancer is dependent on the pathological response
- Expression of hypoxia-inducible factor 1-'alfa' and vascular endothelial growth factor-C in locally advanced breast cancer patients
- Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy
- Mouse renal 4T1 cell engraftment as a model to study the influence of hypoxia in breast cancer progression
- Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer
- Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer
- Genetic profile analysis of tumor stem cells in locally advanced breast cancer
- Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy
- Germ cells and mammary gland transcritome comparison generate a powerful gene expression profile that predicts breast cancer survival
- IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
